The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The global Tyrosine Protein Kinase JAK1 market size is expected to gain market growth in the forecast period of 2020 to 2025.
MarketsandResearch.biz has announced a new report (July 2020) entitled Global Tyrosine Protein Kinase JAK1 Market 2020 by Manufacturers, Type and Application, Forecast to 2025 which presents definitions and classifications of the market. It highlights the market scenario in key regions along with country-level insights for the global Tyrosine Protein Kinase JAK1 market players to track opportunities. Manufacturers can expand their business globally and establish their presence. Moreover, the report also throws light on the recent growth strategies by the market vendors. The new entrants, as well as the existing players, can plan activities and gain top position in the coming years.
The report notes the below as the “key players”
The major players covered in Tyrosine Protein Kinase JAK1 are: AbbVie Inc, Concert Pharmaceuticals Inc, AstraZeneca Plc, Aclaris Therapeutics Inc, CJ HealthCare Corp, Astellas Pharma Inc, Galapagos NV, Chipscreen Biosciences Ltd, Bristol-Myers Squibb Co, Eli Lilly and Co, Pfizer Inc, Theravance Biopharma Inc, Incyte Corp, Portola Pharmaceuticals Inc, Nissan Chemical Industries Ltd, Japan Tobacco Inc, Vectura Group Plc, SAREUM HOLDINGS PLC, Jiangsu Hengrui Medicine Co Ltd, etc.
Sections on the report belonging to SAR:
2.18 Sareum Holdings Plc
2.18.1 Sareum Holdings Plc Details
2.18.2 Sareum Holdings Plc Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Sareum Holdings Plc SWOT Analysis
2.18.4 Sareum Holdings Plc Product and Services
2.18.5 Sareum Holdings Plc Tyrosine Protein Kinase JAK1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Full report here:
https://www.marketsandresearch.biz/report/66877/global-tyrosine-protein-kinase-jak1-market-2020-by-manufacturers-type-and-application-forecast-to-2025
Sample report here:
https://www.marketsandresearch.biz/sample-request/66877
So that means in the last week
1. SRRA’s Chief Business Officer has acquired 100,000 shares (12/08/20) at market price ($12.05):
https://www.sec.gov/Archives/edgar/data/1290149/000120919120046213/xslF345X03/doc4.xml
2. SRRA’s Chief Reg & Tech Ops Officer has also acquired 100,000 shares at market price ($12.05):
https://flashalert.me/?symbol=SRRA&source=SEC&referer=https://stocktwits.com/&url=https://www.sec.gov/Archives/edgar/data/1290149/000120919120045576/xslF345X03/doc4.xml&s3=SRRA/2020-08-06/18-53-44_000000/4/131cc1a2aa0c6923f472296e9d278756/doc4.xml
That is a total of $2,410,000 or $1,205,000 each
2 Wall Street analysts have issued ratings and price targets for Sierra Oncology in the last 12 months. Their average twelve-month price target is $34.00, suggesting that the stock has a possible upside of 180.99%. The high price target for SRRA is $48.00 and the low price target for SRRA is $20.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
https://www.marketbeat.com/stocks/NASDAQ/SRRA/price-target/
Thanks Stoney, that’s interesting news! Hopefully all
Will be revealed soon!
Does anybody know when FPA started building their holding in SAR?
Apologies if this has been posted before, but this is DP’s recent interview with Stockbox re. The most recent shallow drill results, similarities to the Mount Wright tenement, updates on Zinc and Copperhead/Copperdome plus my favourite quote of DP’s from the interview:
“We’re not interested in lifestyle companies!”
https://www.pscp.tv/w/cfwYmnR3LTI2OTk1OTU5fDFuQUtFQURkTndZS0yD79gedgkSvhDZlfTL9W7C2QOJtaLeV2wIb-_bPyB9sg==?t=6m15s
I see 100,000 SIERRA shares were acquired, yesterday, by Turner William D. (SRRA Chief Reg & Tech Ops Officer) AS reported in a new form 4 filed with the SEC:
https://newsfilter.io/a/131cc1a2aa0c6923f472296e9d278756
Morning Sareumites!
Found this interesting study, published on 25th June 2020) on the use of Gilteritinib (a FMS-like tyrosine kinase-3 (FLT3) inhibitor) as a treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19):
https://onlinelibrary.wiley.com/doi/10.1111/bjh.16962
The study concludes that the FLT3 inhibitor can be safely administered and induce remission in patients presenting with de novo FLT 3-ITD-positive AML and Covid-19.
Could the Chinese firm who licensed our FLT3+Aurora inhibitor be conducting similar studies...
Morning Sareumites!Found this interesting study, published on 25th June 2020) on the use of Gilteritinib (a FMS-like tyrosine kinase-3 (FLT3) inhibitor) as a treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19):https://onlinelibrary.wiley.com/doi/10.1111/bjh.16962The study concludes that the FLT3 inhibitor can be safely administered and induce remission in patients presenting with de novo FLT 3-ITD-positive AML and Covid-19.Could the Chinese firm who licensed our FLT3+Aurora inhibitor be conducting similar studies...
20 July 2020
Rockfire Resources plc
("Rockfire" or the "Company")
Deep diamond drilling commences at Plateau
Rockfire Resources plc (LON: ROCK) the gold and base metal exploration company, is pleased to announce that diamond drilling down to 500m depth is now underway at the Company's 100%-owned Plateau Gold Deposit ("Plateau"), part of the Lighthouse tenement in North Queensland, Australia.
Highlights:
· Six diamond drill holes are currently planned to test the gold mineralisation down to 500m vertical depth.
· This is the fourth drilling programme since October 2019, which continues the Company's aggressive exploration strategy, aimed at discovering a large economic gold deposit at Plateau.
· Assay results from the June 2020 reverse circulation drilling programme are still pending. The market will be updated once the results are received from the laboratory.
· The six planned deeper holes are expected to be completed over the coming months.
David Price, Chief Executive Officer of Rockfire commented:
"It is pleasing and exciting to have the diamond drilling underway at Plateau. Gold mineralisation has been encountered in multiple holes within the top 200m from surface, so the next step in our exploration is to test down to 500m depth. Below 300m from surface is where the main gold mineralised zone was discovered at the nearby Mt Wright gold mine, where more than 1.5M ounces of gold was mined down to 1,200m depth."
"The Company is keenly awaiting the results from our reverse circulation drilling completed in June 2020. During that programme, five holes were drilled down to 250m depth and intersected visible sulphides over broad intervals of several hundred metres and were located up to 100m east of previous drilling."
"We look forward to progressively updating the market as our exploration progresses."
The 304.23k trade on SRRA was at 6:48:43 for 10.50p.
* The 7 trades that came before this range between 10.87 and 10.77
* The 7 trades that came after this range between 10.85 and 10.97
Yet the SP rises 12.20% up for the day.
Curious and curiouser
Hi Krispy,
see my post for 1st July:
TSTR breaks 200 day moving average!1 Jul '20
Zac Mir from Sharetalk charts TSTR’s performance, noting the 200 day moving average being broken and forecasting a near term SP rise of up to 37p
https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-1st-july-2020/#gs.9ppgo1
Cheers and hold for Gold (and antimony of course!)
Zac Mir from Sharetalk charts TSTR’s performance, noting the 200 day moving average being broken and forecasting a near term SP rise of up to 37p
https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-1st-july-2020/#gs.9ppgo1
GLA
I’m with you Belhus and ColdFishPie!
To me, it’s shows that the directors are confident in the company’s current position and the current share price, well actually the placing price of 0.6p (a premium of current SP).
GLA
Some great research there RMM, good work!
As we can all see, cogs are turning and the info is out there. But like a lot of posters on this board have rightly pointed out, Sareum aren’t directly publicising all of it. Why is that? Because of 1 of the 3 reasons you have listed? Maybe/Probably? But like you say, it is difficult to decipher whether the snippets we have are good or bad.
Although, with all that being said, I vote we keep the faith and believe in the science! The puzzle pieces are on the table Sareumites! All TM has to do now is....put them together and complete! ;)
GLA
Haha sounds like we were on the same journey yesterday RMM, as mine lead me back to Eli Lilly and also the same conclusion about B-Family DNA polymerases too! Let’s hope all is revealed soon
GLA
As we all know, Eli Lilly were were working on Prexasertib, a CHK-1 inhibitor which it picked up from Array Bio Pharma and Roche were working on another CHK-1 inhibitor, but both were abandoned:
https://www.evaluate.com/vantage/articles/news/snippets/lilly-scraps-two-research-assets-leaving-few-rivals-behind
HOWEVER: the ICR believes CHK1 inhibitors could have a bright future as part of combination strategies aimed at forcing cancer cells to die. Aphidicolin is an unsuitable blocker of B-family DNA polymerases, however, because it is too toxic to be used in people. So the research team is now searching for suitable drug candidates that can block the polymerase family. They have said that once they land on one, they plan to test it alongside SRA737 or other CHK1 blockers in animal studies.
GLA
Morning Sareumites!
Hope all are well.
Again, apologies if this has already been posted, but stumbled across an interesting read this morning.
The below is a cancer research journey published by British researchers on 11th March 2020:
https://cancerres.aacrjournals.org/content/early/2020/03/10/0008-5472.CAN-19-1372
As you can see researchers say they have found a potential new use for SRA-737, which could greatly expand its target patient population. Scientists at the ICR and the University of Kent discovered that combining SRA-737 with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.
The team started by treating lung and bowel cancer cells with Just SRA-737. Then they looked for a way to increase the ability of the drug to kill cancer cells by screening genes for other targets that could be blocked.
In so doing, they landed on the B-family of DNA polymerases, which are proteins that help to ensure that DNA copies are accurate. When they inhibited B-family DNA polymerases with a compound called aphidicolin, and combined it with our SRA-737, they observed higher amounts of cell death in 8 of the 9 cell lines they tested!
Check out this quote from Professor Paul Workman, the CEO of the ICR, and the co-lead author of the study:
“We found that doubling up on drugs that target the systems for repairing DNA could be effective even against cancers that do not respond to single-drug treatment”
The other co-leader of the study, Professor Michelle Garrett, previously a Team Leader at the ICR, now Professor of Cancer Therapeutics at the University of Kent, said:
"Our study shows the potential of targeting DNA replication for adding to the effect of an existing drug that blocks a system that helps respond to DNA damage.
"The next step is to develop new drug candidates that could be used to target B-family DNA polymerases in combination with the CHK1 inhibitor SRA737, as we have shown that this could open up a potential new therapeutic approach."
They discovered that low levels of the polymerases can be detected in some tumors. Therefore, they suggested, tumor testing could be used on patients most likely to respond to a combination of SRA737 and inhibition of B-family DNA polymerases.
Full statement here:
https://www.eurekalert.org/pub_releases/2020-03/iocr-tao031120.php
Hello all,
Apologies if this has already been posted. But Just seen this on AddisInsight, which for those who don’t know, is a database for drug research and development, disease treatment and decision making. It is based on trusted, scientifically sound data, which is reviewed, assessed and summarized by a team of expert scientists. They provide results on drugs, trials, deals, safety and patents.
Anyway, I stumbled across the SRA-737 profile:
https://adisinsight.springer.com/drugs/800045596
As you can see, it states:
04 Jun 2020
SRA 737 is available for licensing as of 04 Jun 2020. https://www.sierraoncology.com/
Was SRA-737 only put up in the shop window 2 weeks ago? On AddisInsight’s drug profile, they have linked to the SRRA site for onlicensing....but as we all know, this has now been taken down off.
Make of that what you will Sareumites!
GLA
Hi 308,
What was on that BBC link as the page has now been removed?
Thanks
Road to Resilience: How Aston Martin is protecting and engaging their employees, communities and customers
Road to Resilience is a series to inspire, educate, and unite our UK&I community during these unprecedented times. Hosted by Naga Munchetty, an award winning journalist and broadcaster, this 4 episode series will highlight local Trailblazers and dive into their stories of resilience, adaptation, and innovation now and into the future.
Please welcome Peter Freedman, VP & Chief Marketing Officer at Aston Martin, as he discusses how Aston Martin have reacted to this challenging and rapidly changing landscape by protecting and engaging their employees, communities and customers.